The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Oxazole derivatives-based cancer drug compositions. Buy the report here.

Smarter leaders trust GlobalData

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity. 

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have. 

110 innovations will shape the pharmaceutical industry 

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry. 

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry. 

Innovation S-curve for the pharmaceutical industry 

Oxazole derivatives-based cancer drug compositions is a key innovation area in the pharmaceutical industry

Oxazoles, which have oxygen and nitrogen atoms present within their core structure, enable interactions with different enzymes and receptors. Oxazole derivatives possess potent anticancer activity by inhibiting targets such as STAT3 and G-quadruplex. They also inhibit tubulin protein to induce apoptosis in cancer cells. Other targets such as DNA topoisomerase enzyme, protein kinases, and miscellaneous targets including Cdc25, mitochondrial enzymes, HDAC, LSD1, HPV E2 TAD, NQO1, aromatase, BCl-6, estrogen receptor, GRP-78, and Keap-Nrf2 pathway are inhibited by oxazole derivatives.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 60+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of oxazole derivatives-based cancer drug compositions.

Key players in oxazole derivatives-based cancer drug compositions – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to oxazole derivatives-based cancer drug compositions

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
F. Hoffmann-La Roche 195 Unlock Company Profile
Vertex Pharmaceuticals 160 Unlock Company Profile
Arbutus Biopharma 100 Unlock Company Profile
HEC Pharm Group 91 Unlock Company Profile
Pfizer 72 Unlock Company Profile
Betta Pharmaceuticals 56 Unlock Company Profile
Kirin Holdings 53 Unlock Company Profile
Alnylam Pharmaceuticals 49 Unlock Company Profile
Johnson & Johnson 43 Unlock Company Profile
Orion Holdings 40 Unlock Company Profile
AbbVie 38 Unlock Company Profile
C. H. Boehringer Sohn 37 Unlock Company Profile
Jiangsu Hengrui Medicine 35 Unlock Company Profile
Beijing Scitech-MQ Pharmaceuticals 34 Unlock Company Profile
Daiichi Sankyo 34 Unlock Company Profile
BioMarin Pharmaceutical 28 Unlock Company Profile
Cancer Research UK 27 Unlock Company Profile
E. Merck 27 Unlock Company Profile
Pierre Fabre Foundation 27 Unlock Company Profile
Incyte 24 Unlock Company Profile
Bayer 23 Unlock Company Profile
Triphase Accelerator 22 Unlock Company Profile
Bristol-Myers Squibb 22 Unlock Company Profile
Teva Pharmaceutical Industries 21 Unlock Company Profile
Actuate Therapeutics 20 Unlock Company Profile
PIQUR Therapeutics 19 Unlock Company Profile
Capella Therapeutics 19 Unlock Company Profile
Zydus Lifesciences 19 Unlock Company Profile
Zhejiang Beta Pharma 19 Unlock Company Profile
Forma Therapeutics Holdings 18 Unlock Company Profile
Capulus Therapeutics 18 Unlock Company Profile
TransThera Sciences (Nanjing) 16 Unlock Company Profile
IRM 16 Unlock Company Profile
Raze Therapeutics 15 Unlock Company Profile
Cancer Research Technology 15 Unlock Company Profile
TaiRx 15 Unlock Company Profile
Capgemini 15 Unlock Company Profile
Beta Pharma 14 Unlock Company Profile
Infinity Pharmaceuticals 13 Unlock Company Profile
ExonHit Therapeutics 13 Unlock Company Profile
Innate Pharma 12 Unlock Company Profile
Hanmi Science 11 Unlock Company Profile
Merck & Co 11 Unlock Company Profile
Mitsubishi Chemical Group 11 Unlock Company Profile
Gvk Davix Technologies Pvt. 11 Unlock Company Profile
Strides Pharma Science 11 Unlock Company Profile
Sumitomo Chemical 11 Unlock Company Profile
Eli Lilly and 9 Unlock Company Profile
Araxes Pharma 9 Unlock Company Profile
North & South Brother Pharmacy Investment 9 Unlock Company Profile

Source: GlobalData Patent Analytics

F. Hoffmann-La Roche is the leading patent filer of oxazole derivatives-based cancer drug compositions. The company develops drugs and diagnostics to treat major diseases. Its product range includes medicines for the treatment of cancer, auto-immune diseases, central nervous system diseases, ophthalmological disorders, infectious diseases, and respiratory diseases. Vertex Pharmaceuticals and Arbutus Biopharma are the other key patent filers of oxazole derivatives-based cancer drug compositions.

In terms of application diversity, Alnylam Pharmaceuticals is the top company, followed by Arbutus Biopharma and Forma Therapeutics. By means of geographic reach, Alnylam Pharmaceuticals also holds the top position. Whilst C. H. Boehringer Sohn and Teva Pharmaceutical Industries stand in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.